Healthcare -
Medical - Devices - NASDAQ - US
$ 1.085
-4.35 %
$ 6.73 M
Market Cap
-0.1
P/E
1. INTRINSIC VALUE
2. FUNDAMENTAL
ANALYSIS
Price Chart TNON
FINANCIALS
Balance Sheet
Tenon Medical, Inc.
| Current Assets | 8.21 M |
| Cash & Short-Term Investments | 6.54 M |
| Receivables | 863 K |
| Other Current Assets | 812 K |
| Non-Current Assets | 1.63 M |
| Long-Term Investments | 0 |
| PP&E | 1.15 M |
| Other Non-Current Assets | 482 K |
| Current Liabilities | 1.87 M |
| Accounts Payable | 369 K |
| Short-Term Debt | 287 K |
| Other Current Liabilities | 1.21 M |
| Non-Current Liabilities | 2 M |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 2 M |
EFFICIENCY
Earnings Waterfall
Tenon Medical, Inc.
| Revenue | 3.28 M |
| Cost Of Revenue | 1.57 M |
| Gross Profit | 1.71 M |
| Operating Expenses | 15.5 M |
| Operating Income | -13.8 M |
| Other Expenses | -93 K |
| Net Income | -13.7 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Tenon Medical, Inc.
| Net Income | -13.7 M |
| Depreciation & Amortization | 655 K |
| Capital Expenditures | -186 K |
| Stock-Based Compensation | 3.84 M |
| Change in Working Capital | -746 K |
| Others | -630 K |
| Free Cash Flow | -10.1 M |
Wall Street Analysts Price Targets
Tenon Medical, Inc.
TNON has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
TNON does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Tenon Medical, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Tenon Medical, Inc. Announces Timing of First Quarter 2025 Financial Results
LOS GATOS, CA / ACCESS Newswire / April 29, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced plans to release financial results for the first quarter 2025 ended March 31, 2025 after market close on Tuesday, May 13, 2025. The Company will also hold a conference call on the same day at 4:30 p.m.
accessnewswire.com
- 2 weeks ago
Tenon Medical, Inc. Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
LOS GATOS, CA / ACCESS Newswire / March 25, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today announced it has entered into a securities purchase agreement with a single healthcare focused institutional investor for the issuance and sale of 1,271,500 shares of its common stock (or common stock equivalents in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules at a purchase price of $2.00. In a concurrent private placement (the "Private Placement" and together with the registered offering, the "Offerings"), the Company also agreed to issue to the same investor warrants to purchase up to 1,271,500 shares of its common stock (the "Common Warrants").
accessnewswire.com
- 1 month ago
Tenon Medical, Inc. Announces a Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
LOS GATOS, CA / ACCESS Newswire / March 25, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today announced it has entered into a securities purchase agreement with a single healthcare focused institutional investor for the issuance and sale of 733,500 shares of its common stock (or common stock equivalents in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules at a purchase price of $2.00. In a concurrent private placement (the "Private Placement" and together with the registered offering, the "Offerings"), the Company also agreed to issue to the same investor warrants to purchase up to 733,500 shares of its common stock (the "Common Warrants").
accessnewswire.com
- 1 month ago
Tenon Medical(R) Announces FDA Clearance of Catamaran(R) SI Joint Fusion System for New Indication to Augment Spinal Fusion
~ Achieves Significant Milestone with Expanded Use Indication, Opens Sizable New SI Market Opportunity ~ LOS GATOS, CA / ACCESS Newswire / March 24, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, announced today that the U.S. Food and Drug Administration (FDA) has provided clearance of an expanded indication for the Catamaran® SI Joint Fusion System (the "Catamaran") for use in augmenting thoracolumbar fusion. With this approval, the Catamaran is now indicated to treat the SI joint as either a stand-alone treatment or to augment a spinal fusion.
accessnewswire.com
- 1 month ago
Tenon Medical, Inc. (TNON) Q4 2024 Earnings Call Transcript
Tenon Medical, Inc. (NASDAQ:TNON ) Q4 2024 Earnings Conference Call March 20, 2025 4:30 PM ET Company Participants Steve Foster - President and CEO Kevin Williamson - Chief Financial Officer Conference Call Participants Anthony Vendetti - Maxim Group Operator Greetings. And welcome to the Tenon Medical Fourth Quarter and Full Year 2024 Financial Results and Corporate Update Conference Call.
seekingalpha.com
- 1 month ago
Tenon Medical Reports Fourth Quarter and Full Year 2024 Financial Results
~ Full Year 2024 Revenue of $3.3 Million, a 12% Increase Compared to Prior Year ~ ~ Interim Analysis from MAINSAIL Study Reinforces Safety Profile, Effectiveness and Confirmation of Fusion ~ ~ Catamaran® SI Joint Fusion Technology Protected with Robust Patent Portfolio of Twelve U.S. and International Patents ~ ~ Introduced Catamaran SE Platform and Successfully Completed Initial Clinical Procedures ~ ~ National Commercial Launch of Catamaran SE in Mid-2025 ~ LOS GATOS, CA / ACCESS Newswire / March 20, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today reported financial results for the fourth quarter and year ended December 31, 2024. Financial Results and Business Updates Fourth Quarter 2024 Results: Revenue of $0.8 million, in line with the fourth quarter of 2023.
accessnewswire.com
- 1 month ago
Tenon Medical, Inc. Announces a Warrant Inducement Transaction for $3.0 Million in Gross Proceeds
LOS GATOS, CA / ACCESS Newswire / March 11, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacroiliac joint (SI Joint) disorders, today announced its entry into a warrant inducement agreement with an existing healthcare-focused institutional investor of the Company for the immediate exercise of Series A Warrants to purchase up to 1,222,850 shares of common stock (the "Series A Warrants") and Series B Warrants to purchase up to 1,222,850 shares of common stock (the "Series B Warrants", and together with the Series A Warrants the "Existing Warrants") at a reduced exercise price of $1.25 for gross cash proceeds of approximately $3.0 million, before deducting financial advisor fees and other transaction expenses. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.
accessnewswire.com
- 2 months ago
Tenon Medical(R) Receives Approval for Notice of Allowance from the European Patent Office
LOS GATOS, CA / ACCESS Newswire / March 10, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, announced today the Company has been notified by the European patent office that two additional patents directed to the novel Catamaran SI Joint Fixation Device have been approved for grant of a European patent within the European Community. "The Tenon Medical team is pleased to receive recognition from the European Community for our novel Catamaran® SI joint prostheses," commented Richard Ginn, Co-Founder and Chief Technology Officer of Tenon Medical.
accessnewswire.com
- 2 months ago
Tenon Medical, Inc. Announces Timing of Fourth Quarter and Full Year 2024 Financial Results
LOS GATOS, CA / ACCESS Newswire / March 7, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced plans to release financial results for the fourth quarter and full year 2024 ended December 31, 2024 after market close on Thursday, March 20, 2025. The Company will also hold a conference call the same day at 4:30 p.m.
accessnewswire.com
- 2 months ago
Tenon Medical(R) to Host Meetings During the 2025 J.P. Morgan Healthcare Conference in San Francisco
LOS GATOS, CA / ACCESSWIRE / January 9, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced that Chief Financial Officer Kevin Williamson will host one-on-one investor meetings in San Francisco, CA during the week of January 13th in accordance with the 43rd Annual J.P. Morgan Healthcare Conference.
accesswire.com
- 4 months ago
Tenon Medical, Inc. (TNON) Q3 2024 Earnings Call Transcript
Tenon Medical, Inc. (NASDAQ:TNON ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Steven Foster - President & CEO Kevin Williamson - CFO Conference Call Participants Anthony Vendetti - Maxim Group Operator Greetings, and welcome to the Tenon Medical Third Quarter 2024 Financial Results and Corporate Update Conference Call. As a reminder, this call is being recorded.
seekingalpha.com
- 6 months ago
Tenon Medical Reports Third Quarter 2024 Financial Results
~ 3Q Revenue of $0.9 Million, Consistent with Prior Quarter; Year to Date Revenue of $2.5 Million, Growth of 18.3% Compared to Prior Year ~ ~ Published Interim Analysis from MAINSAIL™ Study; Post-Market Study Supports the Safety and Efficacy of the Catamaran SI Joint Fusion System® Including Radiographic Proof of Fusion ~ ~ Initial Clinical Procedures Completed with New Catamaran SE Platform ~ ~ Granted Issuance of Three U.S. Patents ~ ~ Received Net Proceeds of ~$9.6 Million from Equity Financing Transactions ~ LOS GATOS, CA / ACCESSWIRE / November 13, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today reported financial results for the third quarter ended September 30, 2024. Third Quarter 2024 and Subsequent Highlights Revenue of $0.9 Million in the third quarter of 2024, a 1.6% decrease over the second quarter of 2024.
accesswire.com
- 6 months ago
8. Profile
Summary
Tenon Medical, Inc. TNON
COUNTRY
US
INDUSTRY
Medical - Devices
MARKET CAP
$ 6.73 M
Dividend Yield
0.00%
Description
Tenon Medical, Inc., a medical device company, develops surgical implant systems to optimize sacroiliac joint fixation/fusion surgery and corresponding outcomes. It sells The CATAMARAN SIJ Fusion System that includes instruments and implants designed to prepare and fixate the SI-Joint for fusion in the United States and Puerto Rico. The company was founded in 2012 and is based in Los Gatos, California.
Contact
104 Cooper Court, Los Gatos, CA, 95032
https://www.tenonmed.com
IPO
Date
April 27, 2022
Employees
27
Officers
Mr. Steven M. Foster
Chief Executive Officer, President & Director
Mr. Richard Ginn
Founder, Chief Technology Officer & Director
Mr. Steve Moscaret
Senior Vice President of Sales & Marketing
Mr. Kevin Williamson
Chief Financial Officer
Mr. Richard M. Ferrari
Founder & Executive Chairman